Role of probiotics in prevention of antibiotic associated diarrhea in Pediatrics.

Role of Bacillus clausii in prevention of antibiotic associated diarrhea in Pediatrics.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202406832389998

Enrollment

Registered

2024-06-11

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System antibiotic associated diarrhea Paediatrics

Interventions

Prophylactic treatment with a probiotic for patients receiving antibiotics.

received distilled water ampoules as placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Children with any condition necessitating antibiotic therapy, oral or intravenous. ? Within 24 hours from the start of the antibiotic therapy. ? Age range 4 months to 12 years old. ? Any sex.

Exclusion criteria

Exclusion criteria: ? Patients with diarrhea prior to antibiotic therapy, or of any known etiology, acute or chronic. ? Patients receiving antibiotics to which B. clausii organisms are sensitive including: Chloramphenicol, Rifampicin, Streptomycin and Tetracycline. ? Immunodeficiency. ? Use of a probiotic product for any reason in the previous 7 days to the actual condition.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of B. clausii, as an adjunctive treatment to antibiotic therapy, in preventing or minimizing antibiotic-associated diarrhea in children.	—

Secondary

Measure	Time frame
To assess the incidence of antibiotic-associated diarrhea in Egyptian children and in relation to various types of commonly used antibiotics.	—

Countries

Egypt

Contacts

Public ContactAfaf enayet

kasr alainy faculty of medicine

afaf_enayet@hotmail.com01223811148

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026